NASDAQ:CBLI Cleveland BioLabs Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.00 +0.03 (+1.52 %) (As of 10/1/2020 12:00 AM ET) Add Compare Share Today's Range$1.95Now: $2.00▼$2.0250-Day Range$1.65MA: $2.13▼$2.6952-Week Range$0.50Now: $2.00▼$5.00Volume53,066 shsAverage Volume931,707 shsMarket Capitalization$26.03 millionP/E RatioN/ADividend YieldN/ABeta0.67 ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cleveland BioLabs. Previous Next 3.2 Community Rank Outperform VotesCleveland BioLabs has received 276 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCleveland BioLabs has received 155 “underperform” votes. (Add your “underperform” vote.)Community SentimentCleveland BioLabs has received 64.04% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote “Outperform” if you believe CBLI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCleveland BioLabs does not currently pay a dividend.Dividend GrowthCleveland BioLabs does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cleveland BioLabs insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.88% of the stock of Cleveland BioLabs is held by insiders.Percentage Held by InstitutionsOnly 3.20% of the stock of Cleveland BioLabs is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCleveland BioLabs has a P/B Ratio of 22.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.64 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBLI Previous Symbol CUSIPN/A CIK1318641 Webwww.cbiolabs.com Phone716-849-6810Debt Debt-to-Equity RatioN/A Current Ratio5.17 Quick Ratio5.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.11 million Price / Sales23.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book22.22Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-2,650,000.00 Net Margins-246.88% Return on Equity-125.63% Return on Assets-82.66%Miscellaneous EmployeesN/A Outstanding Shares13,016,000Market Cap$26.03 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $2.00 +0.03 (+1.52 %) (As of 10/1/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CBLI News and Ratings via Email Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter. Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions How has Cleveland BioLabs' stock price been impacted by COVID-19 (Coronavirus)? Cleveland BioLabs' stock was trading at $3.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CBLI shares have decreased by 36.5% and is now trading at $2.00. View which stocks have been most impacted by COVID-19. When is Cleveland BioLabs' next earnings date? Cleveland BioLabs is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Cleveland BioLabs. How were Cleveland BioLabs' earnings last quarter? Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) EPS for the quarter. The biotechnology company earned $0.16 million during the quarter. Cleveland BioLabs had a negative return on equity of 125.63% and a negative net margin of 246.88%. View Cleveland BioLabs' earnings history. Are investors shorting Cleveland BioLabs? Cleveland BioLabs saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 270,100 shares, an increase of 89.4% from the August 31st total of 142,600 shares. Based on an average trading volume of 1,420,000 shares, the short-interest ratio is presently 0.2 days. Approximately 4.8% of the company's shares are sold short. View Cleveland BioLabs' Short Interest. Who are some of Cleveland BioLabs' key competitors? Some companies that are related to Cleveland BioLabs include BIOQUAL (BIOQ), Auxly Cannabis Group (CBWTF), Bioanalytical Systems (BASI), NanoViricides (NNVC), ProMIS Neurosciences (ARFXF), AIkido Pharma (AIKI), Tenax Therapeutics (TENX), Inhibitor Therapeutics (INTI), HedgePath Pharmaceuticals (HPPI), Vitality Biopharma (VBIO), US Stem Cell (USRM), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY), Deltagen (DGEN) and DNAPrint Genomics (DNAG). View all competitors. What other stocks do shareholders of Cleveland BioLabs own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include Ibio (IBIO), Inovio Pharmaceuticals (INO), Opko Health (OPK), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Biocept (BIOC) and Co-Diagnostics (CODX). Who are Cleveland BioLabs' key executives? Cleveland BioLabs' management team includes the following people: Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, CEO & Interim Principal Financial Officer (Age 46)Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 65)Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 63)Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory AffairsDr. Andrei Purmal Ph.D., VP of Chemistry What is Cleveland BioLabs' stock symbol? Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI." How do I buy shares of Cleveland BioLabs? Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cleveland BioLabs' stock price today? One share of CBLI stock can currently be purchased for approximately $2.00. How big of a company is Cleveland BioLabs? Cleveland BioLabs has a market capitalization of $26.03 million and generates $1.11 million in revenue each year. What is Cleveland BioLabs' official website? The official website for Cleveland BioLabs is www.cbiolabs.com. How can I contact Cleveland BioLabs? Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected] This page was last updated on 10/1/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
